georgeclerk J.P. Morgan upgraded Solid Biosciences (NASDAQ:SLDB) from neutral to outperform, sending shares of the biotech up 10% Monday. The firm also raised its price target to $15 from $10 (~89% upside based on July 12 close). Analyst Anupam Rama believes that a recent label expansion for Sarepta Therapeutics’ (SRPT)Continue Reading
jewhyte Microsoft (NASDAQ:MSFT) is seeing “solid demand” going into its fiscal fourth-quarter results, due in part to a “modest” acceleration in its Azure cloud service, Morgan Stanley said. Shares were little changed in premarket trading on Monday. “Expect Microsoft to meet buyside expectations for a modest acceleration in Azure growthContinue Reading
Axe_Olga/iStock via Getty Images Copper (HG1:COM), (COPX), (CPER) started the year up 30% through May 20, but later dropped 13% since then. However, the fundamentals have not changed for the commodity, “financial speculators were a bit too optimistic to start the year and pushed prices beyond base fundamentals,” analysts, headedContinue Reading
SlavkoSereda/iStock via Getty Images Crude oil futures settle lower on the day while notching a fourth straight weekly increase, helped by a much larger than expected drop in U.S. crude inventories, renewed hopes that the U.S. Federal Reserve might start cutting interest rates soon, and heightened geopolitical risks in theContinue Reading
